Caregivers of people living with dementia experience significant stress which can negatively affect their mental health. The goal of our study is to test a newly developed app that focuses on providing stress management strategies for caregivers of people living with dementia.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change from baseline in the Perceived Stress Scale-10 (PSS-10) total scores at 8-weeks
Timeframe: The PSS-10 will be administered at baseline (i.e., prior to starting the study) and immediately after the end of the intervention period (i.e., after a 8-week period)
Change from baseline in the Perceived Stress Scale-10 (PSS-10) total scores at a 4-week follow-up
Timeframe: The PSS-10 will be administered at baseline (i.e., prior to starting the study) and at a 4-week follow-up period
Change from after the 8-week period in the Perceived Stress Scale-10 (PSS-10) total scores at a 4-week follow-up
Timeframe: The PSS-10 will be administered immediately after the 8-week period and at a 4-week follow-up period
Change from baseline in the Burden Scale for Family Caregivers-Short Version (BSFC-S) total scores at 8-weeks
Timeframe: The BSFC-S will be administered at baseline (i.e., prior to starting the study) and immediately after the end of the intervention period (i.e., after a 8-week period)
Change from baseline in the BSFC-S total scores at a 4-week follow-up
Timeframe: The BSFC-S will be administered at baseline (i.e., prior to starting the study) and at a 4-week follow up
Change from after the 8-week period in the BSFC-S total scores at a 4-week follow-up
Timeframe: The BSFC-S will be administered immediately after the 8-week period and at a 4-week follow-up period
Change from baseline in the Patient Health Questionnaire-9 (PHQ-9) total scores at 8-weeks
Timeframe: The PHQ-9 will be administered at baseline (i.e., prior to starting the study) and immediately after the end of the intervention period (i.e., after a 8-week period)
Change from baseline in the PHQ-9 total scores at a 4-week follow-up
Timeframe: The PHQ-9 will be administered at baseline (i.e., prior to starting the study) and at a 4-week follow-up period
Change from after the 8-week period in the PHQ-9 total scores at a 4-week follow-up
Timeframe: The PHQ-9 will be administered immediately after the 8-week period and at a 4-week follow-up period
Change from baseline in the Generalized Anxiety Disorder-7 (GAD-7) total scores at 8-weeks
Timeframe: The GAD-7 will be administered at baseline (i.e., prior to starting the study) and immediately after the end of the intervention period (i.e., after a 8-week period)
Change from baseline in the GAD-7 total scores at a 4-week follow-up
Timeframe: The GAD-7 will be administered at baseline (i.e., prior to starting the study) and at a 4-week follow up period
Change from after the 8-week period in the GAD-7 total scores at a 4-week follow-up
Timeframe: The GAD-7 will be administered immediately after the 8-week period and at a 4-week follow-up period